Prof. dr Mirjana Gotić
Specijalista interne medicine, subspecijalista hematolog
Obrazovanje :
- 1977-1983 Doktor medicine, Medicinski fakultet Univerziteta u Beogradu
- 1984-1988 Postdiplomske studije iz Hematologije, Medicinski fakultet Univerziteta u Beogradu
- 1990 Academic Haematology and Cytogentics, Royal Marsden Hospital, London, (Head Prof. Dr. Daniel Catovsky), Stipendija Ministarstva za nauku, Republike Srbije
- 1988 – 1992 Specializacija iz Interne medicine, Institut za Hematologiju, Univerzitetski klinički centar, Beograd
Akademska karijera:
- 1989 Magistar medicinskih nauka (Mr sci med) Medicinski fakultet Univerziteta u Beogradu
- 1991-1999 Asistent na Katedri Interne medicine, n.b. Kinika za hematologiju, Medicinski Fakultet Univerziteta u Beogradu
- Jun 1998 Doktor medicinskih nauka (Dr sci med) Medicinski fakultet Univerziteta u Beogradu
- 1999-2004 Docent na katedri Interne medicine, n.b. Kinika za hematologiju, Medicinski Fakultet Univerziteta u Beogradu
- 2004–2011 Vanredni profesor na katedri Interne medicine, n.b. Kinika za hematologiju Medicinski Fakultet Univerziteta u Beogradu
- od 2011 Redovni profesor na katedri Interne medicine, n.b. Kinika za hematologiju Medicinski Fakultet Univerziteta u Beograd
Radno iskustvo:
- 1986 – 1992 Doktor medicine Institut za hematologije Univerzitetski klinički centar Beograd
- 1992 – 2024 Specijalista Interne medicine, Institut (Klinika) za hematologije, Klinički centar Srbije, Beograd
- 2008 – 2024 Subspecijalista iz hematologije, Klinika za hematologije, Klinički centar Srbije, Beograd
- 2001- 2022 Načelnik Polikliničko-dijagnostičkog odeljenja Klinike za hematologiju Kliničkog centra Srbije, Beograd
- 2022 – 2024 Šef Kabineta za mijeloproliferativne neoplazme Klinike za hematologiju Univerzitetskog Kliničkog centra Srbije u Beogradu
Članstva:
od 1983 Član Srpskog lekarskog društva
od 1994 Član European Hematology Association
2002 – 2005 Član uređivačkog odbora časopisa „The Journal of the Hellenic Society of Haematology“
od 2009 Član Central European Myeloproliferative Study Organisation (CEMPO)
od 2011 Član Uredništva časopisa “Srpski Arhiv za celokupno lekarstvo SLD-a”
2011-2014 Predsednik Hematološke sekcije SLD
2016- 2022 Vanredni član Akademije medicinskih nauka Srpskog lekarskog društva
od 2022 Redovni član Akademije medicinskih nauka Srpskog lekarskog društva
Nacionalni istraživački projekti:
2002-2005 Projekat MNTR, br. 1682, pod nazivom: „Molekularno-biološka detekcija minimalne rezidualne bolesti u hroničnim limfoidnim leukemijama i njen uticaj na preživljavanje bolesnika“, Nosilac projekta Prof dr Mirjana Gotić
2006 – 2010 Projekakt MNTR, br. 145048, pod nazivom: “Ćelijski i molekularni mehanizmi regulacije hematopoeze” Nosilac projekta Prof dr Pavle Milenković, Istraživač saradnik Prof dr Mirjana Gotić
2011 – 2022 Projekakt MNTR, br. 175053, pod nazivom:“Ispitivanje patogeneze hematoloških maligniteta”, Nosilac projekta Naučni saradnik Dr sci med dr Vladan Čokić, Istraživač saradnik Prof dr Mirjana Gotić
Internacionalni projekti i kliničke studije:
1992-1997 „An open protocol for the use of Agrelin (Anagrelide) for patients with thrombocythemia“, Project No 282, Protocol No 292-024 COINVESTIGATOR
1989-1992 „Pentostatin in Patients with Active Hairy Cell Leukemia Previously Treated with Interferon Alpha” Protocol No 188-0015, Group C Treatment Protocol, COINVESTIGATOR
2003-2003 „SPD422-306 ANAGRELIDE RETROSPECTIVE DATA COLLECTION STUDY“, PRINCIPLE INVESTIGATOR
2003-2005 „A phase III study to evaluate the efficacy and safety of front line therapy with alemtuzumab (Campath, MabCampath) vs chlorambucil in patients with progressive B-cell chronic lymphocytic leukaemia, CAM307“, INVESTIGATOR
2005-2007 „A single blind, multi-centre, randomised multinational Phase III Study to compare the efficacy and tolerability of Anagrelide vs Hydroxyurea in patients with essential thrombocythemia, ANAHYDRET², PRINCIPLE INVESTIGATOR
2006-2007 Study group Indolent Lymphomas: “Therapy Optimization Study for the Treatment of Hairy Cell Leukemia, Subcutaneous Use of Cladribine in Hairy Cell Leukemia”, INVESTIGATOR
2007-2008 “A Phase II, open-label, multicentre, pharmacokinetic, pharmacodynamics and safety study of anagrelide hydrochloride in young (18-50 years) and elderly (³ 65 years) patients with essential thrombocythaemia, SPD422-203“, PRINCIPLE INVESTIGATOR
2007- 2008 “A Phase II trial to evaluate the efficacy and safety of subcutaneously administered alemtuzumab (CAMPATHâ, MabCampathâ) in patients with previously treated B-cell Chronic Lymphocytic Leukaemia, CAM203“, INVESTIGATOR
2007 – 2010 “A Phase IIIb, randomised, open label study to compare the safety, efficacy and tolerability of anagrelide hydrochloride versus hydroxyurea in high-risk essential thrombocythaemia patients, SPD422-403“, PRINCIPLE INVESTIGATOR for Serbia
2009 – 2016 COORDINATING PRINCIPLE INVESTIGATOR for European Union and Eastern Europe
2012 – 2014 „A Randomized, Open-label, Phase 3 Study of Carfilzomib vs Best Supportive Care in Subjects with Relapsed and Refractory Multiple Myeloma, PX-171-011“, PRINCIPLE INVESTIGATOR
2016 -2017 ‘A Pivotal Multicenter Trial of Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia, CD-ON-CAT-8015-1053“, PRINCIPLE INVESTIGATOR
From 2021 “A Randomized Controlled Phase 3 Study of Pacritinib Versus Physician¢s Choice on Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelet Counts <50,000/mL), PACIFICA, PAC303“, PRINCIPLE INVESTIGATOR
2021-2023 „An Open –Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 with TL-895 in Subjects with Relapsed/Refractory Myelofibrosis and KRT-232 in Janus-associated Kinase Inhibitor-Intolerant Myelofibrosis, KRT-232-113“, PRINCIPLE INVESTIGATOR
Nagrade i publikacije:
2018 Nagrada za naučno-istraživački rad Srpskog lekarskog društva
Broj prezentovanih i publikovanih radova: > 400
(90 radova “in extenso” u Pub Med bazi podataka)
Broj citata (Google Academic): 1707
h-index: 19